303 related articles for article (PubMed ID: 2374641)
21. [Treatment of anemia in patients with chronic kidney insufficiency in hemodialysis with erythropoietin].
Prata MM; de Sousa FT; Barbas JV; da Costa AM; Vinhas J; Moreira P; Abrantes C; Lopes MC
Acta Med Port; 1990; 3(3):149-53. PubMed ID: 2220424
[TBL] [Abstract][Full Text] [Related]
22. [The treatment of anemia in patients on hemodialysis with recombinant human erythropoietin].
Borrego FJ; Miguel JL; Zamorano A; Muñoz J; Bajo A; López-Revuelta K; Sánchez Sicilia L
Med Clin (Barc); 1991 Nov; 97(18):687-92. PubMed ID: 1770818
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human erythropoietin therapy in haemodialysis patients--dose determination and clinical experience.
Bommer J; Alexiou C; Müller-Bühl U; Eifert J; Ritz E
Nephrol Dial Transplant; 1987; 2(4):238-42. PubMed ID: 3118264
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
[TBL] [Abstract][Full Text] [Related]
25. [The use of recombinant erythropoietin with patients on programmed hemodialysis].
Rozental' RL; Zezina LIu; Spudass AV
Ter Arkh; 1991; 63(12):110-3. PubMed ID: 1803587
[TBL] [Abstract][Full Text] [Related]
26. [Optimal therapy with erythropoietin (EPO) in patients with renal anemia on hemodialysis therapy].
Merta M; Sobotová D; Zahálková J; Bitterová Z; Jirka T; Knetl P; Kopenec J; Suchanová J; Vlasák J
Sb Lek; 2001; 102(1):41-52. PubMed ID: 11830918
[TBL] [Abstract][Full Text] [Related]
27. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
28. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
[TBL] [Abstract][Full Text] [Related]
29. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of anemia in hemodialysis patients using recombinant human erythropoietin: advantages and disadvantages].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1989 Mar; 119(9):269-75. PubMed ID: 2711161
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
[TBL] [Abstract][Full Text] [Related]
32. [Use of erythropoietin in children with terminal renal insufficiency treated with chronic hemodialysis].
Peco-Antić A; Popović-Rolović M; Jovanović O; Kostić M; Kruscić D
Srp Arh Celok Lek; 1992; 120(5-6):147-52. PubMed ID: 1465668
[TBL] [Abstract][Full Text] [Related]
33. Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin.
Bárány P; Pettersson E; Ahlberg M; Hultman E; Bergström J
Clin Nephrol; 1991 Jun; 35(6):270-9. PubMed ID: 1873941
[TBL] [Abstract][Full Text] [Related]
34. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
35. [Anemia management in haemodialysis. EuCliD database in Spain].
Avilés B; Coronel F; Pérez-García R; Marcelli D; Orlandini G; Ayala JA; Rentero R
Nefrologia; 2002; 22(6):555-63. PubMed ID: 12516289
[TBL] [Abstract][Full Text] [Related]
36. [Therapy of renal anemia with recombinant human erythropoietin].
Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
[TBL] [Abstract][Full Text] [Related]
37. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
Bárány P; Pettersson E; Konarski-Svensson JK
Nephrol Dial Transplant; 1993; 8(5):426-32. PubMed ID: 8393547
[TBL] [Abstract][Full Text] [Related]
38. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
39. [Arterial hypertension in patients with chronic kidney insufficiency in hemodialysis with erythropoietin].
Martins Prata M; Teixeira de Sousa F; Barbas J; Vinhaś J; Marques da Costa A
Rev Port Cardiol; 1990 Feb; 9(2):119-23. PubMed ID: 2346662
[TBL] [Abstract][Full Text] [Related]
40. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
